Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Silver Spring, Md., May 29, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for...
-
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
-
Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology
Omniscient (o8t®) secures $27.2M Series D funding to scale its AI-powered Quicktome® brain mapping platform and accelerate personalized brain care globally
-
Icelandirect contract manufacturer of supplements, vitamins, and nutraceuticals for human and pet brands, completes its FSSC 22000 Version 6 certification.
-
Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.
-
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”;...
-
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
Silver Spring, MD, May 20, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration announced today that it issued warning letters to eight retailers for selling unauthorized tobacco products,...